HYDROXOCOBALAMIN- hydroxocobalamin injection, solution Actavis Pharma, Inc.

HYDROXOCOBALAMIN INJECTION USP Rx Only


DESCRIPTION

Hydroxocobalamin injection is a sterile solution of hydroxocobalamin for intramuscular administration.

Each mL contains: Hydroxocobalamin Acetate equivalent to 1000 mcg Hydroxocobalamin, Sodium Acetate Anhydrous 0.2 mg, Glacial Acetic Acid 0.442 mg, Sodium Chloride 8.2 mg, with Methylparaben 1.5 mg and Propylparaben 0.2 mg as preservatives, in Water for Injection q.s. Additional Glacial Acetic Acid and/or Sodium Acetate may have been used to adjust pH. pH range is 3.5 to 5.0.

Hydroxocobalamin appears as dark red orthorhombic needles or as an amorphous or crystalline red powder. It is very hygroscopic in the anhydrous form, and moderately soluble in water. It has a molecular weight of 1346.37. The vitamin B_{12} coenzymes are very unstable in light. Hydroxocobalamin shares the cobalamin molecular structure with cyanocobalamin.

The chemical name is α -(5,6-dimethylbenzimidazoly) hydroxocobamide. The empirical formula is $C_{62}H_{89}CoN_{13}O_{15}P$ and its structural formula is:



The cobalt content is 4.34%.

CLINICAL PHARMACOLOGY

Vitamin B_{12} is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis.

Fifty percent of the administered dose of hydroxocobalamin disappears from the injection site in 2.5 hours. Hydroxocobalamin is bound to plasma proteins and stored in the liver. It is excreted in the bile and undergoes some enterohepatic recycling. Within 72 hours after injection of 500 to 1000 mcg of hydroxocobalamin, 16 to 66 percent of the injected dose may appear in the urine. The major portion is excreted within the first 24 hours.

INDICATIONS AND USAGE

- I. Pernicious anemia, both uncomplicated and accompanied by nervous system involvement.
- II. Dietary deficiency of Vitamin B₁₂, occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B₁₂ deficiency is very rare).
- III. Malabsorption of vitamin B₁₂, resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B₁₂ absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B₁₂ deficiency.
- IV. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B₁₂ deficiency. Structural lesions leading to vitamin B₁₂ deficiency include regional ileitis, ileal resections, malignancies, etc.
- V. Competition for Vitamin B_{12} by intestinal parasites or bacteria.

The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B_{12} and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B_{12} or folate.

- VI. Inadequate utilization of vitamin B_{12} . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.
- VII. For the Schilling Test.

CONTRAINDICATION

Hypersensitivity to any component of this medication.

WARNINGS

Avoid the intravenous route.

Folic acid is not a substitute for vitamin B_{12} although it may improve vitamin B_{12} deficient megaloblastic anemia. Exclusive use of folic acid in treating vitamin B_{12} deficient megaloblastic anemia could result in progressive and irreversible neurologic damage.

Blunted or impeded therapeutic response to vitamin B_{12} may be due to such conditions as infection, uremia, drugs having bone marrow suppressant properties such as chloramphenicol, and concurrent iron or folic acid deficiency.

PRECAUTIONS

General

The validity of diagnostic vitamin B_{12} or folic acid blood assays could be compromised by medications, and this should be considered before relying on such tests for therapy.

Vitamin B_{12} is not a substitute for folic acid and since it might improve folic acid deficient megaloblastic anemia, indiscriminate use of vitamin B_{12} could mask the true diagnosis.

Hypokalemia and thrombocytosis could occur upon conversion of severe megaloblastic to normal erythropoiesis with B_{12} therapy. Therefore, serum potassium levels and the platelet count should be monitored carefully during therapy.

Vitamin B₁₂ deficiency may suppress the signs of polycythemia vera. Treatment with vitamin B₁₂ may

unmask this condition.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies of carcinogenicity, mutagenesis, or impairment of fertility have not been performed with hydroxocobalamin.

Pregnancy

Teratogenic Effects: Pregnancy Category C: Animal reproduction studies have not been conducted with hydroxocobalamin. It is also not known whether hydroxocobalamin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hydroxocobalamin should be given to a pregnant woman only if clearly needed.

ADVERSE REACTIONS

Mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis.

A few patients may experience pain after injection of hydroxocobalamin.

To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.

OVERDOSAGE

The intravenous LD_{50} of hydroxocobalamin in mice is greater than 50 mL/kg.

DOSAGE AND ADMINISTRATION

Protect from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Hydroxocobalamin injection should be given only intramuscularly.

In patients with Addisonian Pernicious Anemia, parenteral therapy with vitamin B_{12} is the recommended method of treatment and will be required for the remainder of the patient's life. Oral therapy is not dependable. In other patients with vitamin B_{12} deficiency, the duration of therapy and route of administration will depend upon the cause and whether or not it is reversible.

Confirmatory diagnostic studies should be performed prior to initiating therapy, if possible, and the patient should be followed with appropriate studies to demonstrate hematologic improvement (Hgb, hematocrit, RBC, reticulocyte count). A diagnostic trial utilizing physiologic doses of vitamin B_{12} (1 mcg daily) and observing daily reticulocyte counts after establishing a baseline may also be performed. The observation of reticulocytosis which usually occurs between the third and tenth day of therapy confirms the diagnosis of vitamin B_{12} deficiency.

In seriously ill patients it may be advisable to administer both vitamin B_{12} and folic acid while awaiting the results of distinguishing laboratory studies. It is not necessary to withhold vitamin B_{12} therapy until the precise cause of B_{12} deficiency is established since absorption studies can be performed at any time.

Serum potassium should be closely observed the first 48 hours and potassium should be administered if necessary.

Treatment of Vitamin B₁₂ Deficiency

Thirty mcg daily for 5 to 10 days followed by 100 to 200 mcg monthly injected intramuscularly. If the patient is critically ill, or has neurologic disease, an infectious disease or hyperthyroidism, considerably higher doses may be indicated. However, current data indicate that the optimum obtainable neurologic response may be expected with a dosage of vitamin B_{12} sufficient to produce good hematologic response. Children may be given a total of 1 to 5 mg over a period of 2 or more weeks in doses of 100 mcg, then 30 to 50 mcg every 4 weeks for maintenance.

Patients who have normal intestinal absorption may be treated with an oral therapeutic multivitamin preparation, containing 15 mcg vitamin B_{12} daily.

Schilling Test

The flushing dose is 1000 mcg.

HOW SUPPLIED

Hydroxocobalamin Injection USP, 1000 mcg/mL is available in a 30 mL multiple dose vial, individually boxed.

Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.] **PROTECT FROM LIGHT.**

Literature revised: January 2017

Manufactured by: **Hikma Farmaceutica** (Portugal) S.A. 2705-906 Terrugem SNT, Portugal

Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA

PIN229-WAT/2

PRINCIPAL DISPLAY PANEL


NDC 0591-2888-30 30 mL Sterile Multiple Dose Vial

Hydroxocobalamin Injection USP

30,000 mcg/30 mL (1,000 mcg/mL)

FOR INTRAMUSCULAR USE ONLY

Actavis Rx only



HYDROXOCOBALAMIN hydroxocobalamin injection, solution

Product InformationProduct TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0591-2888Route of AdministrationINTRAMUSCULARItem Code (Source)Item Code (Source)

g-cuic	nt/Active Moiety			
	Ingredient Name	Ba	sis of Strength	Strength
HYDRO XO COBALAMIN ACETATE (UNII: S535M27N3Q) (HYDRO XOCOBALAMIN - HY UNII:Q40 X8 H422O) HY		N - HYDI	ROXOCOBALAMIN	1000 ug in 1 mL
Inactive Ingred	ients			
Ingredient Name			Strength	
SODIUM ACETATE ANHYDROUS (UNII: NVG71ZZ7P0)			0.2 mg in 1 mL	
ACETIC ACID (UNII: Q40Q9N063P)			0.442 mg in 1 mL	
SODIUM CHLORIDE (UNII: 451W47IQ8X)			8.2 mg in 1 mL	
METHYLPARABEN (UNII: A218 C7 HI9 T)			1.5 mg in 1 mL	
PROPYLPARABEN (UNII: Z8IX2SC1OH)			0.2 mg in 1 mL	
PROPILPARABEN	(01411. 2017/2301011)		0.2 mg m i mL	
WATER (UNII: 059Q			0.2 mg m i mL	
WATER (UNII: 059Q				
WATER (UNII: 059Q		Marketing Date	Start Marke	ting End Date
water (UNII: 059Q Packaging	F0KO0R)	•	Start Marke	-
WATER (UNII: 059Q Packaging # Item Code 1 NDC:0591-2888- 30	FOKOOR) Package Description	Date	Start Marke	-
WATER (UNII: 059Q Packaging # Item Code 1 NDC:0591-2888-	F0KO0R) Package Description 1 in 1 CARTON 30 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination	Date	Start Marke	-
WATER (UNII: 059Q Packaging # Item Code 1 NDC:0591-2888- 30	F0KO0R) Package Description 1 in 1 CARTON 30 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination	Date	Start Marke	-
WATER (UNII: 059Q) Packaging # Item Code 1 NDC:0591-2888-30 1	Package Description 1 in 1 CARTON 30 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product	Date	Start Marke	-
WATER (UNII: 059Q) Packaging # Item Code 1 NDC:0591-2888- 30	Package Description 1 in 1 CARTON 30 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product	Date	Start Marke	Date

Labeler - Actavis Pharma, Inc. (119723554)

Revised: 12/2017

Actavis Pharma, Inc.